Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02630693
Title Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications

Her2-receptor negative breast cancer

Therapies

Palbociclib

Fulvestrant

Tamoxifen

Age Groups: adult
Covered Countries CAN


No variant requirements are available.